Skip to main content
SpringerLink
Log in

Methods for Assessing the Preventability of Adverse Drug Events

A Systematic Review

  • Systematic Review
  • Published:
Drug Safety Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background: Preventable adverse drug events (ADEs) are common in both outpatient and inpatient settings. However, the proportion of preventable ADEs varies considerably in different studies, even when conducted in the same setting, and methods for assessing the preventability of ADEs are diverse.

Objective: The aim of this article is to identify and systematically evaluate methods for assessing the preventability of ADEs.

Data sources: Seven databases (Cochrane, CINAHL, EMBASE, IPA, MEDLINE, PsycINFO and Web of Science) were searched in September 2010 utilizing the databases’ index terms and other common terminology on preventable ADEs. No limits for the years of publication were set. Reference lists of included original articles and relevant review articles were also screened.

Study selection: After applying predetermined inclusion and exclusion criteria on 4161 unique citations, 142 (3.4%) original research articles were included in the review. One additional article was included from reference lists. Outcome measures of included studies had to include the frequency of ADEs and the assessment of their preventability. Studies were excluded if they focused on individuals with one specific type of treatment, medical condition, medical procedure or ADE.

Data extraction: Measurement instruments for determining the preventability of ADEs in each article were extracted and unique instruments were compared. The process of assessing the preventability of ADEs was described based on reported actions taken to standardize and conduct the assessment, and on information about the reliability and validity of the assessment.

Data synthesis: Eighteen unique instruments for determining the preventability of ADEs were identified. They fell under the following four groups: (i) instruments using a definition of preventability only (n=3); (ii) instruments with a definition of preventability and an assessment scale for determining preventability (n=5); (iii) instruments with specific criteria for each preventability category (n=3); and (iv) instruments with an algorithm for determining preventability (n=7). Of actions to standardize the assessment process, performing a pilot study was reported in 21 (15%), and use of a standardized protocol was reported in 18 (13%), of the included 143 articles. Preventability was assessed by physicians in 86 (60%) articles and by pharmacists in 41 (29%) articles. In 29 (20%) articles, persons conducting the assessment were described as trained for or experienced in preventability assessment. In 94 (66%) articles, more than one person assessed the preventability of each case. Among these 94 articles, assessment was done independently in 73 (51%) articles. Procedures for managing conflicting assessments were diverse. The reliability of the preventability assessment was tested in 39 (27%) articles, and 16 (11%) articles referred to a previous reliability assessment. Reliability ranged from poor to excellent (kappa 0.19–0.98; overall agreement 26–97%). Four (3%) articles mentioned assessing validity, but no sensitivity or specificity analyses or negative or positive predictive values were presented.

Conclusions: Instruments for assessing the preventability of ADEs vary from implicit instruments to explicit algorithms. There is limited evidence for the validity of the identified instruments, and instrument reliability varied significantly. The process of assessing the preventability of ADEs is also commonly imprecisely described, which hinders the interpretation and comparison of studies. For measuring the preventability of ADEs more accurately and precisely in future, we believe that existing instruments should be further studied and developed, or that one or more new instruments should be developed, and the validity and reliability of the existing and new instruments be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Table III

Similar content being viewed by others

References

  1. de Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care 2008; 17(3): 216–23

    PubMed  Google Scholar 

  2. Masotti P, McColl MA, Green M. Adverse events experienced by homecare patients: a scoping review of the literature. Int J Qual Health Care 2010; 22(2): 115–25

    PubMed  Google Scholar 

  3. Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13(4): 306–14

    PubMed  CAS  Google Scholar 

  4. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63(2): 136–47

    PubMed  CAS  Google Scholar 

  5. Thomsen LA, Winterstein AG, Sondergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41(9): 1411–26

    PubMed  Google Scholar 

  6. Krahenbuhl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007; 30(5): 379–407

    PubMed  Google Scholar 

  7. Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60(17): 1750–9

    PubMed  Google Scholar 

  8. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274(1): 29–34

    PubMed  CAS  Google Scholar 

  9. Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995; 21(10): 541–8

    PubMed  CAS  Google Scholar 

  10. van Doormaal JE, Mol PG, van den Bemt PM, et al. Reliability of the assessment of preventable adverse drug events in daily clinical practice. Pharmacoepidemiol Drug Saf 2008; 17(7): 645–54

    PubMed  Google Scholar 

  11. Ferner RE, Aronson JK. Preventability of drug-related harms, part I: a systematic review. Drug Saf 2010; 33(11): 985–94

    PubMed  Google Scholar 

  12. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531–6

    PubMed  CAS  Google Scholar 

  13. Even in best-run centers, preventable medication errors lengthen LOS, increase costs. Health Care Cost Reengineering Rep 1998; 3(10): 149–51

    Google Scholar 

  14. Bell D. Cooperative approach to medication errors. Sth Hosp 1974; 42(9): 12–20

    Google Scholar 

  15. Hulley SB, Martin JN, Cummings SR. Planning the measurement: precision and accuracy. In: Hulley SB, Cummings SR, Browner WS, et al., editors. Designing clinical research. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2007: 37–50

    Google Scholar 

  16. Streiner DL, Norman GR. Reliability. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 126–52

    Google Scholar 

  17. Streiner DL, Norman GR. Validity. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 173–93

    Google Scholar 

  18. van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17(4): 365–71

    PubMed  Google Scholar 

  19. Olivier P, Boulbes O, Tubery M, et al. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf 2002; 25(14): 1035–44

    PubMed  Google Scholar 

  20. Letrilliart L, Hanslik T, Biour M, et al. Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study. Drug Saf 2001; 24(10): 781–92

    PubMed  CAS  Google Scholar 

  21. Calderon-Ospina C, Bustamante-Rojas C. The DoTS classification is a useful way to classify adverse drug reactions: a preliminary study in hospitalized patients. Int J Pharm Pract 2010; 18(4): 230–5

    PubMed  Google Scholar 

  22. Farcas A, Sinpetrean A, Mogosan C, et al. Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania. Eur J Intern Med 2010; 21(5): 453–7

    PubMed  Google Scholar 

  23. Jönsson AK, Hakkarainen KM, Spigset O, et al. Preventable drug related mortality in a Swedish population. Pharmacoepidemiol Drug Saf 2010; 19(2): 211–5

    PubMed  Google Scholar 

  24. Lopez LC, Botero M, Pino J, et al. Adverse drug reactions in internal medicine units at a university hospital: a descriptive pilot study. Colomb Medica 2010; 41(1): 45–51

    Google Scholar 

  25. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4(2): e4439

    PubMed  Google Scholar 

  26. Pourseyed S, Fattahi F, Pourpak Z, et al. Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 2009; 18(2): 104–10

    PubMed  Google Scholar 

  27. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 2008; 19(7): 505–10

    PubMed  Google Scholar 

  28. Al-Malaq HM, Al-Aqeel SA, Al-Sultan MS. Adverse drug reactions related hospitalization identified by discharge ICD-9 codes in a university hospital in Riyadh. Saudi Med J 2008; 29(8): 1145–50

    PubMed  Google Scholar 

  29. Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 2008; 102(4): 408–11

    PubMed  CAS  Google Scholar 

  30. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008; 31(6): 545–56

    PubMed  Google Scholar 

  31. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in Scotland. Pharm World Sci 2008; 30(6): 854–62

    PubMed  Google Scholar 

  32. Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf 2009; 18(7): 639–45

    PubMed  Google Scholar 

  33. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65(3): 396–406

    PubMed  Google Scholar 

  34. Ruiz B, Garcia M, Aguirre U, et al. Factors predicting hospital readmissions related to adverse drug reactions. Eur J Clin Pharmacol 2008; 64(7): 715–22

    PubMed  Google Scholar 

  35. Subish P, Mishra P, Shankar PR. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal. Pak J Pharm Sci 2008; 21(4): 465–7

    Google Scholar 

  36. Grenouillet-Delacre M, Verdoux H, Moore N, et al. Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med 2007; 33(12): 2150–7

    PubMed  CAS  Google Scholar 

  37. Patel KJ, Kedia MS, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007; 7: 8

    PubMed  CAS  Google Scholar 

  38. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64(17): 1840–3

    PubMed  Google Scholar 

  39. Davies EC, Green CF, Mottram DR, et al. Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 2006; 31(4): 335–41

    PubMed  CAS  Google Scholar 

  40. Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61(5): 511–5

    PubMed  Google Scholar 

  41. Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 2006; 54(3): 226–33

    PubMed  Google Scholar 

  42. Dormann H, Neubert A, Criegee-Rieck M, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255(6): 653–63

    PubMed  CAS  Google Scholar 

  43. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15–9

    PubMed  Google Scholar 

  44. Temple ME, Robinson RF, Miller JC, et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004; 27(11): 819–29

    PubMed  Google Scholar 

  45. Dormann H, Criegee-Rieck M, Neubert A, et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26(5): 353–62

    PubMed  Google Scholar 

  46. Easton-Carter KL, Chapman CB, Brien JE. Adverse drug reactions in paediatrics: are we getting the full picture? J Pharm Res 2003; 33(2): 106–10

    Google Scholar 

  47. Easton-Carter KL, Chapman CB, Brien JE. Emergency department attendances associated with drug-related problems in paediatrics. J Paediatr Child Health 2003; 39(2): 124–9

    PubMed  CAS  Google Scholar 

  48. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36(9): 1331–6

    PubMed  Google Scholar 

  49. Wasserfallen J, Livio F, Buclin T, et al. Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 2001; 12(5): 442–7

    PubMed  Google Scholar 

  50. Lagnaoui R, Moore N, Fach J, et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56(2): 181–6

    PubMed  CAS  Google Scholar 

  51. Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33(2): 236–40

    PubMed  CAS  Google Scholar 

  52. Schumock GT, Seeger JD, Kong SX. Control charts to monitor rates of adverse drug reactions. Hosp Pharm 1995; 30(12): 1088, 1091–2, 1095–6

    PubMed  CAS  Google Scholar 

  53. Pearson TF, Pittman DG, Longley JM, et al. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994; 51(18): 2268–72

    PubMed  CAS  Google Scholar 

  54. Kramer MS, Hutchinson TA, Flegel KM, et al. Adverse drug reactions in general pediatric outpatients. J Pediatr 1985; 106(2): 305–10

    PubMed  CAS  Google Scholar 

  55. Choonara IA, Harris F. Adverse drug reactions in medical inpatients. Arch Dis Child 1984; 59(6): 578–80

    PubMed  CAS  Google Scholar 

  56. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8(6): 289–94

    PubMed  CAS  Google Scholar 

  57. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285(16): 2114–20

    PubMed  CAS  Google Scholar 

  58. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348(16): 1556–64

    PubMed  Google Scholar 

  59. Winterstein AG, Hatton RC, Gonzalez-Rothi R, et al. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm 2002; 59(18): 1742–9

    PubMed  Google Scholar 

  60. Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. J Gerontol A Biol Sci Med Sci 1998; 53(1): M59–63

    PubMed  CAS  Google Scholar 

  61. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995; 274(1): 35–43

    PubMed  CAS  Google Scholar 

  62. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277(4): 307–11

    PubMed  CAS  Google Scholar 

  63. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997; 25(8): 1289–97

    PubMed  CAS  Google Scholar 

  64. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280(15): 1311–6

    PubMed  CAS  Google Scholar 

  65. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5(3): 305–14

    PubMed  CAS  Google Scholar 

  66. Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 1999; 159(21): 2553–60

    PubMed  CAS  Google Scholar 

  67. Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999; 6(4): 313–21

    PubMed  CAS  Google Scholar 

  68. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282(3): 267–70

    PubMed  CAS  Google Scholar 

  69. Honigman B, Lee J, Rothschild J, et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001; 8(3): 254–66

    PubMed  CAS  Google Scholar 

  70. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107–16

    PubMed  Google Scholar 

  71. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52(8): 1349–54

    PubMed  Google Scholar 

  72. Field TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc 2004; 11(6): 492–8

    PubMed  Google Scholar 

  73. Field TS, Gilman BH, Subramanian S, et al. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005; 43(12): 1171–6

    PubMed  Google Scholar 

  74. Kopp BJ, Erstad BL, Allen ME, et al. Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 2006; 34(2): 415–25

    PubMed  Google Scholar 

  75. Field TS, Mazor KM, Briesacher B, et al. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc 2007; 55(2): 271–6

    PubMed  Google Scholar 

  76. Kaushal R, Goldmann DA, Keohane CA, et al. Adverse drug events in pediatric outpatients. Ambul Pediatr 2007; 7(5): 383–9

    PubMed  Google Scholar 

  77. Wang JK, Herzog NS, Kaushal R, et al. Prevention of pediatric medication errors by hospital pharmacists and the potential benefit of computerized physician order entry. Pediatrics 2007; 119(1): e77–85

    PubMed  Google Scholar 

  78. Zandieh SO, Goldmann DA, Keohane CA, et al. Risk factors in preventable adverse drug events in pediatric outpatients. J Pediatr 2008; 152(2): 225–31

    PubMed  Google Scholar 

  79. Takata GS, Taketomo CK, Waite S, et al. Characteristics of medication errors and adverse drug events in hospitals participating in the California Pediatric Patient Safety Initiative. Am J Health Syst Pharm 2008; 65(21): 2036–44

    PubMed  Google Scholar 

  80. Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm 2004; 61(14): 1466–72

    PubMed  Google Scholar 

  81. Franklin BD, Birch S, Schachter M, et al. Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm Pract 2010; 18(5): 305–11

    PubMed  Google Scholar 

  82. Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J Gen Intern Med 2010; 25(1): 31–8

    PubMed  Google Scholar 

  83. Benkirane R, Pariente A, Achour S, et al. Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study. East Mediterr Health J 2009; 15(5): 1145–55

    PubMed  CAS  Google Scholar 

  84. Benkirane RR, Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf 2009; 5(1): 16–22

    PubMed  Google Scholar 

  85. Kunac DL, Kennedy J, Austin N, et al. Incidence, preventability, and impact of adverse drug events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study. Paediatr Drugs 2009; 11(2): 153–60

    PubMed  Google Scholar 

  86. Gurwitz JH, Field TS, Rochon P, et al. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc 2008; 56(12): 2225–33

    PubMed  Google Scholar 

  87. Hwang SH, Lee S, Koo HK, et al. Evaluation of a computer-based adverse-drug-event monitor. Am J Health Syst Pharm 2008; 65(23): 2265–72

    PubMed  Google Scholar 

  88. Jha AK, Laguette J, Seger A, et al. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Informatics Assoc 2008; 15(5): 647–53

    Google Scholar 

  89. Kaushal R, Bates DW, Abramson EL, et al. Unit-based clinical pharmacists’ prevention of serious medication errors in pediatric inpatients. Am J Health Syst Pharm 2008; 65(13): 1254–60

    PubMed  Google Scholar 

  90. Koneri R, Prakasam K, Mishra V, et al. Drug-related hospitalizations at a tertiary level hospital in Bangalore: a prospective study. J Clin Diagn Res 2008; 2(2): 736–40

    Google Scholar 

  91. Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in New Zealand. N Z Med J 2008; 121(1272): 17–32

    PubMed  Google Scholar 

  92. Saha L, Pandhi P, Malhotra S, et al. Adverse Drug Event (ADE) related medical emergency department visits and hospital admissions: a prospective study from a north India referral India. J Clin Diagn Res 2008; 2(1): 600–4

    Google Scholar 

  93. Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics 2008; 121(4): e927–35

    PubMed  Google Scholar 

  94. Tam KW, Kwok KH, Fan YM, et al. Detection and prevention of medication misadventures in general practice. Int J Qual Health Care 2008; 20(3): 192–9

    PubMed  Google Scholar 

  95. Glassman PA, Belperio P, Lanto A, et al. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Inform Assoc 2007; 14(4): 424–31

    PubMed  Google Scholar 

  96. Holdsworth MT, Fichtl RE, Raisch DW, et al. Impact of computerized prescriber order entry on the incidence of adverse drug events in pediatric inpatients. Pediatrics 2007; 120(5): 1058–66

    PubMed  Google Scholar 

  97. Queneau P, Bannwarth B, Carpentier F, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf 2007; 30(1): 81–8

    PubMed  Google Scholar 

  98. Seger AC, Jha AK, Bates DW. Adverse drug event detection in a community hospital utilising computerised medication and laboratory data. Drug Saf 2007; 30(9): 817–24

    PubMed  CAS  Google Scholar 

  99. Kane-Gill S, Rea RS, Verrico MM, et al. Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit. Am J Health Syst Pharm 2006; 63(19): 1876–81

    PubMed  Google Scholar 

  100. Miller GC, Britth HC, Valenti L. Adverse drug events in general practice patients in Australia. Med J Aust 2006; 184(7): 321–4

    PubMed  Google Scholar 

  101. Schade CP, Hannah K, Ruddick P, et al. Improving self-reporting of adverse drug events in a West Virginia hospital. Am J Med Qual 2006; 21(5): 335–41

    PubMed  Google Scholar 

  102. Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 2006; 166(5): 565–71

    PubMed  Google Scholar 

  103. Walsh KE, Adams WG, Bauchner H, et al. Medication errors related to computerized order entry for children. Pediatrics 2006; 118(5): 1872–9

    PubMed  Google Scholar 

  104. Al-Tajir GK, Kelly WN. Epidemiology, comparative methods of detection, and preventability of adverse drug events. Ann Pharmacother 2005; 39(7–8): 1169–74

    PubMed  Google Scholar 

  105. Forster AJ, Murff HJ, Peterson JF, et al. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005; 20(4): 317–23

    PubMed  Google Scholar 

  106. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118(3): 251–8

    PubMed  Google Scholar 

  107. Mycyk MB, McDaniel MR, Fotis MA, et al. Hospital wide adverse drug events before and after limiting weekly work hours of medical residents to 80. Am J Health Syst Pharm 2005; 62(15): 1592–5

    PubMed  Google Scholar 

  108. Weingart SN, Gandhi TK, Seger AC, et al. Patientreported medication symptoms in primary care. Arch Intern Med 2005; 165(2): 234–40

    PubMed  Google Scholar 

  109. Hardmeier B, Braunschweig S, Cavallaro M, et al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly 2004; 134(45–46): 664–70

    PubMed  Google Scholar 

  110. Holdsworth MT, Fichtl RE, Behta M, et al. Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc Med 2003; 157(1): 60–5

    PubMed  Google Scholar 

  111. Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmacother 2003; 37(1): 5–11

    PubMed  Google Scholar 

  112. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001; 31(4): 199–205

    PubMed  CAS  Google Scholar 

  113. Jha AK, Kuperman GJ, Rittenberg E, et al. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001; 10(2): 113–9

    PubMed  CAS  Google Scholar 

  114. Malhotra S, Jain S, Pandhi P. Drug-related visits to the medical emergency department: a prospective study from India. Int J Clin Pharmacol Ther 2001; 39(1): 12–8

    PubMed  CAS  Google Scholar 

  115. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001; 58(12): 1126–32

    PubMed  CAS  Google Scholar 

  116. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109(2): 87–94

    PubMed  CAS  Google Scholar 

  117. Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63

    PubMed  CAS  Google Scholar 

  118. Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10(4): 199–205

    PubMed  CAS  Google Scholar 

  119. Thomas EJ, Orav EJ, Brennan TA. Hospital ownership and preventable adverse events. Int J Health Serv 2000; 30(4): 745–61

    PubMed  CAS  Google Scholar 

  120. Buckley MS, Erstad BL, Kopp BJ, et al. Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit. Pediatr Crit Care Med 2007; 8(2): 145–52

    PubMed  CAS  Google Scholar 

  121. Ligi I, Arnaud F, Jouve E, et al. Iatrogenic events in admitted neonates: a prospective cohort study. Lancet 2008; 371(9610): 404–10

    PubMed  Google Scholar 

  122. Leape LL, Lawthers AG, Brennan TA, et al. Preventing medical injury. QRB Qual Rev Bull 1993; 19(5): 144–9

    PubMed  CAS  Google Scholar 

  123. Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003; 138(3): 161–7

    PubMed  Google Scholar 

  124. Agarwal S, Classen D, Larsen G, et al. Prevalence of adverse events in pediatric intensive care units in the United States. Pediatr Crit Care Med 2010; 11(5): 568–78

    PubMed  Google Scholar 

  125. Mercier E, Giraudeau B, Ginies G, et al. Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med 2010; 36(6): 1033–7

    PubMed  Google Scholar 

  126. Aranaz-Andres J, Aibar-Remon C, Vitaller-Murillo J, et al. Incidence of adverse events related to health care in Spain: Results of the Spanish National Study of Adverse Events. J Epidemiol Community Health 2008; 62(12): 1022–9

    PubMed  CAS  Google Scholar 

  127. Michel P, Quenon JL, Djihoud A, et al. French national survey of inpatient adverse events prospectively assessed with ward staff. Qual Saf Health Care 2007; 16(5): 369–77

    PubMed  Google Scholar 

  128. Sari AB, Sheldon TA, Cracknell A, et al. Extent, nature and consequences of adverse events: results of a retrospective casenote review in a large NHS hospital. Qual Saf Health Care 2007; 16(6): 434–9

    PubMed  Google Scholar 

  129. Woods DM, Holl JL, Klein JD, et al. Patient safety problems in adolescent medical care. J Adolesc Health 2006; 38(1): 5–12

    PubMed  Google Scholar 

  130. Rothschild JM, Landrigan CP, Cronin JW, et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005; 33(8): 1694–700

    PubMed  Google Scholar 

  131. Woods D, Thomas E, Holl J, et al. Adverse events and preventable adverse events in children. Pediatrics 2005; 115(1): 155–60

    PubMed  Google Scholar 

  132. Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals, II: preventability and clinical context. N Z Med J 2003; 116(1183): U624

    PubMed  Google Scholar 

  133. Darchy B, Le Miere E, Figueredo B, et al. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999; 159(1): 71–8

    PubMed  CAS  Google Scholar 

  134. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228(2): 83–90

    PubMed  CAS  Google Scholar 

  135. Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions: results from an intervention program. Eur J Clin Pharmacol 1993; 45(3): 199–203

    PubMed  CAS  Google Scholar 

  136. Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33(1): 61–8

    PubMed  CAS  Google Scholar 

  137. Hoonhout LHF, De Bruijne MC, Wagner C, et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf 2010; 33(10): 853–64

    PubMed  Google Scholar 

  138. Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. Br J Clin Pharmacol 2009; 67(3): 363–9

    PubMed  Google Scholar 

  139. Rogers S, Wilson D, Wan S, et al. Medication-related admissions in older people: a cross-sectional, observational study. Drugs Aging 2009; 26(11): 951–61

    PubMed  Google Scholar 

  140. Al-Olah YH, Al Thiab KM. Admissions through the emergency department due to drug-related problems. Ann Saudi Med 2008; 28(6): 426–9

    PubMed  Google Scholar 

  141. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(17): 1890–6

    PubMed  Google Scholar 

  142. Witherington EMA, Pirzada OM, Avery AJ. Communication gaps and readmissions to hospital for patients aged 75 years and older: observational study. Qual Saf Health Care 2008; 17(1): 71–5

    PubMed  CAS  Google Scholar 

  143. Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178(12): 1563–9

    PubMed  Google Scholar 

  144. Zargarzadeh AH, Emami MH, Hosseini F. Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 2007; 34(5–6): 494–8

    PubMed  CAS  Google Scholar 

  145. Baena MI, Faus MJ, Fajardo PC, et al. Medicine-related problems resulting in emergency department visits. Eur J Clin Pharmacol 2006; 62(5): 387–93

    PubMed  Google Scholar 

  146. Samoy LJ, Zed PJ, Wilbur K, et al. Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study. Pharmacotherapy 2006; 26(11): 1578–86

    PubMed  Google Scholar 

  147. Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 2004; 57(5): 611–5

    PubMed  Google Scholar 

  148. Howard RL, Avery AJ, Howard PD, et al. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12(4): 280–5

    PubMed  CAS  Google Scholar 

  149. Koh Y, Fatimah BM, Li SC. Therapy related hospital admission in patients on polypharmacy in Singapore: a pilot study. Pharm World Sci 2003; 25(4): 135–7

    PubMed  Google Scholar 

  150. Ng D, Cosh DG, Harris J, et al. Unplanned medication-related admissions to an acute care general teaching hospital. Aust J Hosp Pharm 1999; 29(2): 84–7

    Google Scholar 

  151. Tafreshi MJ, Melby MJ, Kaback KR, et al. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother 1999; 33(12): 1252–7

    PubMed  CAS  Google Scholar 

  152. Easton KL, Parsons BJ, Starr M, et al. The incidence of drug-related problems as a cause of hospital admissions in children. Med J Aust 1998; 169(7): 356–9

    PubMed  CAS  Google Scholar 

  153. Cunningham G, Dodd TR, Grant DJ, et al. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing 1997; 26(5): 375–82

    PubMed  CAS  Google Scholar 

  154. Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164(11): 659–62

    PubMed  CAS  Google Scholar 

  155. Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health Syst Pharm 1996; 53(12): 1422–6

    PubMed  CAS  Google Scholar 

  156. Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy 1996; 16(4): 701–7

    PubMed  CAS  Google Scholar 

  157. Courtman BJ, Stallings SB. Characterization of drug-related problems in elderly patients on admission to a medical ward. Can J Hosp Pharm 1995; 48(3): 161–6

    PubMed  CAS  Google Scholar 

  158. Hallas J, Worm J, Beck-Nielsen J, et al. Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull 1991; 38(5): 417–20

    PubMed  CAS  Google Scholar 

  159. Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988; 109(7): 582–9

    PubMed  CAS  Google Scholar 

  160. Hiatt HH, Barnes BA, Brennan TA, et al. A study of medical injury and medical malpractice. N Engl J Med 1989; 321(7): 480–4

    PubMed  CAS  Google Scholar 

  161. Wilson RM, Runciman WB, Gibberd RW, et al. The Quality in Australian Health Care Study. Med J Aust 1995; 163(9): 458–71

    PubMed  CAS  Google Scholar 

  162. Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals: principal findings from a national survey —occasional paper no 3. Wellington: Ministry of Health, 2001

    Google Scholar 

  163. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47(3): 533–43

    PubMed  CAS  Google Scholar 

  164. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538

    PubMed  CAS  Google Scholar 

  165. Imbs JL, Pletan Y, Spriet A. Assessment of preventable iatrogenic drug therapy: methodology —round table no. 2 at Giens XIII [in French]. Therapie 1998; 53(4): 365–70

    PubMed  CAS  Google Scholar 

  166. Livio F, Buclin T, Yersin B, et al. Hospitalisations pour effet indésirable médicamenteux. Raison de Santé No. 23. Lausanne: Hospices Cantonaux, 1998

    Google Scholar 

  167. Baena MI, Marin R, Martinez-Olmos J, et al. New criteria of assessing preventability of drug-related problems: an updated review based on the experience with 2558 people [in Spanish]. Pharm Care Esp 2002; 4: 393–6

    Google Scholar 

  168. Lau PM, Stewart K, Dooley MJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2003; 37(2): 303–4

    PubMed  Google Scholar 

  169. Olivier P, Caron J, Haramburu F, et al. Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale [in French]. Therapie 2005; 60(1): 39–45

    PubMed  Google Scholar 

  170. Zegers M, de Bruijne MC, Wagner C, et al. The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. J Clin Epidemiol 2010; 63(1): 94–102

    PubMed  Google Scholar 

  171. Kunac DL, Reith DM, Kennedy J, et al. Inter-and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care 2006; 15(3): 196–201

    PubMed  CAS  Google Scholar 

  172. Michel P, Quenon JL, de Sarasqueta AM, et al. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ 2004; 328(7433): 199

    PubMed  Google Scholar 

  173. Thomas EJ, Lipsitz SR, Studdert DM, et al. The reliability of medical record review for estimating adverse event rates. Ann Intern Med 2002; 136(11): 812–6

    PubMed  Google Scholar 

  174. Altman DG. Some common problems in medical research. In: Altman DG, editor. Practical statistics for medical research. 1st ed. Boca Raton (FL): Chapman & Hall/CPC, 1991: 396–439

    Google Scholar 

  175. Snyder RA, Abarca J, Meza JL, et al. Reliability evaluation of the adapted national coordinating council medication error reporting and prevention (NCC MERP) index. Pharmacoepidemiol Drug Saf 2007; 16(9): 1006–13

    PubMed  Google Scholar 

  176. Hayward RA, Hofer TP. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer. JAMA 2001; 286(4): 415–20

    PubMed  CAS  Google Scholar 

  177. Caplan RA, Posner KL, Cheney FW. Effect of outcome on physician judgments of appropriateness of care. JAMA 1991; 265(15): 1957–60

    PubMed  CAS  Google Scholar 

  178. Aronson JK, Ferner RE. Preventability of drug-related harms-part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33(11): 995–1002

    PubMed  Google Scholar 

  179. Streiner DL, Norman GR. Scaling responses. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 29–60

    Google Scholar 

  180. Brennan TA, Localio RJ, Laird NL. Reliability and validity of judgments concerning adverse events suffered by hospitalized patients. Med Care 1989; 27(12): 1148–58

    PubMed  CAS  Google Scholar 

  181. Bryant GD, Norman GR. Expressions of probability: words and numbers. N Engl J Med 1980; 302(7): 411

    PubMed  CAS  Google Scholar 

  182. Williams SD, Ashcroft DM. Medication errors: how reliable are the severity ratings reported to the national reporting and learning system? Int J Qual Health Care 2009; 21(5): 316–20

    PubMed  Google Scholar 

  183. Localio AR, Weaver SL, Landis JR, et al. Identifying adverse events caused by medical care: degree of physician agreement in a retrospective chart review. Ann Intern Med 1996; 125(6): 457–64

    PubMed  CAS  Google Scholar 

  184. Hofer TP, Bernstein SJ, DeMonner S, et al. Discussion between reviewers does not improve reliability of peer review of hospital quality. Med Care 2000; 38(2): 152–61

    PubMed  CAS  Google Scholar 

  185. MacKenzie EJ, Steinwachs DM, Bone LR, et al. Interrater reliability of preventable death judgments. The Preventable Death Study Group. J Trauma 1992; 33(2): 292–302

    PubMed  CAS  Google Scholar 

  186. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4(10): e297

    PubMed  Google Scholar 

  187. International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17(2): 200–8

    Google Scholar 

  188. Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. Drug Saf 2006; 29(11): 1011–22

    PubMed  Google Scholar 

  189. World Health Organization. WHO patient safety research: better knowledge for safer care. Geneva: World Health Organization, 2009

    Google Scholar 

  190. Expert Group on Safe Medication Practices. Creation of a better medication safety culture in Europe: building up safe medication practices. Strasbourg: Council of Europe, 2006

    Google Scholar 

  191. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. EMA/489873/2008: ENCePP code of conduct for scientific independence and transparency in the conduct of pharmacoepidemiological and pharmacovigilance studies. London: European Medicines Agency, 2010

    Google Scholar 

  192. World Health Organization. World alliance for patient safety: forward programme 2008–2009. 1st ed. Geneva: World Health Organization, 2008

    Google Scholar 

  193. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255–9

    PubMed  CAS  Google Scholar 

  194. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations, part II —cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79–90

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Dr Anna K. Jönsson for her contribution to planning of the study, NHV’s librarian Susanne Tidblom-Kjellberger for her advice in conducting the database searches, and Marta Mateos Garcia and Khadidja Hedna for translating references in Spanish and French. The research was conducted as part of the project Drug-Related Morbidity in Sweden (DRUMS), and was funded through an unrestricted grant from the National Corporation of Swedish Pharmacies (Apoteket AB). The funder had no role in the design or conduct of the study, or preparation of the manuscript. The authors have no conflicts of interest directly relevant to content of this review.

Author information

Authors and Affiliations

  1. Nordic School of Public Health (NHV), Box 12133, 402 42, Gothenburg, Sweden

    Katja Marja Hakkarainen, Karolina Andersson Sundell, Max Petzold & Staffan Hägg

  2. Division of Clinical Pharmacology, Linköping University, Linköping, Sweden

    Staffan Hägg

Authors
  1. Katja Marja Hakkarainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karolina Andersson Sundell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max Petzold
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Staffan Hägg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katja Marja Hakkarainen.

Appendix

Appendix

Appendix 1
figure 3

Search strategy

Full size image

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hakkarainen, K.M., Sundell, K.A., Petzold, M. et al. Methods for Assessing the Preventability of Adverse Drug Events. Drug Saf 35, 105–126 (2012). https://doi.org/10.2165/11596570-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11596570-000000000-00000

Keywords

Search

Navigation